

Original Article

Quality of Life Trends in People With and Without Cancer Referred to Volunteer-Provided Palliative Care Services (ELSA): A Longitudinal Study



Catherine Walshe, PhD, Nancy Preston, PhD, Sheila Payne, PhD, Steven Dodd, PhD, and Guillermo Perez Algorta, PhD

The International Observatory on End of Life Care (C.W., N.P., S.P., S.D.), Division of Health Research, Lancaster University, Lancaster; and Division of Health Research (G.P.A.), Lancaster University, Lancaster, UK

Abstract

Context. Trends in symptoms and functional ability are known toward the end of life, but less is understood about quality of life, particularly prospectively following service referral.

Objectives. This study compares quality of life trajectories of people with and without cancer, referred to volunteer-provided palliative care services.

Methods. A secondary analysis of the ELSA trial ($n = 85$ people with cancer and $n = 72$ without cancer) was performed. Quality of life data (WHOQOL-BREF) were collected at baseline (referral), four weeks, eight weeks, and 12 weeks. Sociodemographic data were collected at baseline. We specified a series of joint models to estimate differences on quality of life trajectories between groups adjusting for participants who die earlier in the study.

Results. People with cancer had a significantly better quality of life at referral to the volunteer-provided palliative care services than those with nonmalignant disease despite similar demographic characteristics (Cohen d 's = 0.37 to 0.45). More people with cancer died during the period of the study. We observed significant differences in quality of life physical and environmental domain trajectories between groups ($b = -2.35$, CI $-4.49, -0.21$, and $b = -4.11$, CI $-6.45, -1.76$). People with cancer experienced a greater decline in quality of life than those with nonmalignant disease.

Conclusion. Referral triggers for those with and without cancer may be different. People with cancer can be expected to have a more rapid decline in quality of life from the point of service referral. This may indicate greater support needs, including from volunteer-provided palliative care services. *J Pain Symptom Manage* 2018;56:689–698. © 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Key Words

Palliative care, volunteers, quality of life, pragmatic clinical trial, cancer

Background

Experientially, quality of life for those with life-limiting illness is critically important, as people may prioritize quality of life over treatment that extends its quantity.¹ Palliative care services have a focus on quality of life, but access can be limited or late. Recent data indicate that people with cancer remain likely to

receive aggressive end-of-life interventions including chemotherapy, repeated hospitalizations, ICU admission, and late hospice or palliative care enrollment.^{2,3} Volunteer-provided palliative care services designed to complement clinical care may offer options that facilitate earlier care.^{4,5}

Our study of volunteer-provided palliative care services is the first reported trial in this area.⁶ While the

Address correspondence to: Catherine Walshe, PhD, The International Observatory on End of Life Care, Division of Health Research, Lancaster University, Bailrigg, Lancaster LA1 4AY, UK. E-mail: c.walshe@lancaster.ac.uk

Accepted for publication: July 31, 2018.

intervention effect was small, the longitudinal quality of life data of those referred are a novel addition to knowledge, helping understanding of referral timing and change over time. Studies of quality of life trends for those in the palliative phase of illness are scarce, despite being perceived as an important outcome of trials of palliative care interventions.^{7–9} Understanding trends in quality of life is important both clinically and to improve research so that interventions can be carefully timed, contextualized, and evaluated.^{10–12} Response shift is a particular concern, where people reappraise illness and their quality of life and accommodate its challenges and their perceptions, leading to problems interpreting standard measures over time.^{13,14}

Trajectory data for people toward the end of life tend to focus on functional change, augmented with understandings of social, psychological, and physical change, rather than quality of life.^{15,16} Studies use either qualitative interviews to understand change over time^{16–29} or measure change quantitatively.^{12,28,30–47} Typically, these studies only focus on one diagnosis, track symptoms or functional change rather than quality of life, or use limited data, often from those accessing in-patient clinical services. Some explain the trajectory retrospectively from point of death, but this is less useful clinically due to the inherent problems of prognostication accuracy.⁴⁸ Prospective studies are less common, especially for those referred to nonclinical services.⁴⁹ This study adds to knowledge by reporting longitudinal, prospectively collected, quality of life data, of those expected to be in their last year of life who were referred to volunteer-provided palliative care services.

Patients and Methods

Design

This prospective, longitudinal, multicenter study of people understood to be in their last year of life assessed quality of life in the 12 weeks following referral to a volunteer-provided befriending service. Data were collected in the context of a pragmatic, randomized, prospective waitlist trial; the study protocol and reports are available, and the trial was prospectively registered.^{6,50,51} The aim of this exploratory analysis was to prospectively compare the quality of life of people (with and without cancer) referred to these services.

Participants and Setting

Eligible participants were adults (≥ 18 years) referred to the volunteer-provided palliative care services where the answer to the surprise question “Would you be surprised if the patient dies within a

year?”, assessed by the referring health care professional, was “no.”⁵² They could have any diagnosis. They had to understand or speak a language in which our main outcome measure (the WHOQOL-BREF) was available and have an anticipated prognosis of more than four weeks. The volunteer-provided palliative care services were provided in 11 community settings across England (nine hospices, one alcohol and substance use charity, one NHS Trust). Participants continued to receive all usual care during the study. NHS Research Ethics Committee approval was received, and governance approvals from each participating site. All participants gave written consent.

Data Collection

Data were collected at study entry, and four and eight weeks following that point. Those in the “wait” arm of the trial also provided data at 12 weeks. Quality of life was assessed using the World Health Organisation Quality of Life (WHOQOL-BREF) Scale, a relatively short, but broad (26-item) non-disease specific, validated self-reported measure of quality of life and well-being.⁵³ Data are reported across physical, psychological, environmental, and social relationship domains. Loneliness was assessed with the De Jong Gierveld six-item Loneliness Scale, a short, well-used, reliable, and valid measurement instrument.⁵⁴ Social support was assessed using the eight-item modified Medical Outcomes Study Social Support Survey, a short validated scale covering two domains of emotional and social support.⁵⁵ Additional data included self-reported contact with health and social care services and other networks over the previous two weeks, and baseline sociodemographic data (age, gender, disease diagnosis, education, marital status, living status, spirituality, and ethnicity). Study instruments were self-completed by participants, baseline questionnaires were explained to participants when written consent was taken at a home visit, and subsequent questionnaires were posted to participants’ home address, self-completed, and returned by post to the study team.

Statistical Analysis

Participants were characterized in terms of reported primary diagnosis (cancer vs. noncancer), accounting for no detected difference in primary and secondary outcomes between intervention and control groups.⁶ Baseline characteristics between diagnostic groups were compared using t-test or chi-square test, irrespective of original random treatment allocation. To test for diagnostic status (cancer vs. noncancer) effect on quality of life trajectories, we specified a series of joint models.^{56,57} These joint models simultaneously model the longitudinal outcome (quality of life) of interest and risk of death, by adjusting for participants who

die earlier in the study. In end-of-life studies and those involving older people, a significant proportion of participants may die, with survivors contributing disproportionately larger amounts of data than decedents. The tendency for healthier persons to live longer and contribute more data may lead to a “healthy survivor” effect in estimates obtained from a longitudinal analysis,⁵⁸ so it is important this is accounted for in modeling these data. As part of the joint model, we specified a linear mixed model with intercept and random slopes. We tested the main effect of time and the interaction of time with diagnostic status to evaluate for potential differences in quality of life

trajectories between groups. In the Cox model, we added diagnostic group as a time-independent covariate. We used a (pseudo) adaptive Gauss-Hermite optimization algorithm.⁵⁹ We report parameter estimates, standard errors, and 95% CIs.

Results

Of those referred to the volunteer-provided palliative care services ($n = 329$), 196 consented to take part in the study, and 157 provided evaluable data for this analysis. At each time point, missing data




Fig. 1. Study participant flow.

were noted, but participants continued to be enrolled in the study unless advised otherwise, as data sets could be and often were returned at subsequent time points. Twenty percent of enrolled participants (39 of 196) died during the study. The overall flow through the study is presented in Figure 1. Data were collected during 2015–2016.

Baseline demographic, quality of life, loneliness, and social support data for the 157 participants who provided diagnostic information, enabling these analyses, are presented in Table 1. There were no significant differences on demographic characteristics between those with cancer and with other nonmalignant conditions. Of those without cancer, the study included those with respiratory disease ($n = 26$), neurological disease ($n = 21$), heart failure ($n = 10$), liver disease ($n = 7$), and other forms of life-limiting illness ($n = 8$).

Table 1

Baseline Demographic, Quality of Life, Loneliness, and Social Support Data for Those Who Provided a Diagnosis

Participant Characteristics	People With Cancer Diagnosis, $n = 85$	People With Noncancer Diagnosis, $n = 72$
Age, mean \pm SD	73.28 \pm 11.79	71.24 \pm 12.28
Gender, female, n (%)	52 (61)	47 (65)
Education, standard, n (%) ^a	51 (67)	52 (78)
Marital status, single, n (%) ^b	54 (67)	48 (69)
Living status, living alone, n (%) ^c	47 (57)	42 (61)
Occupation, retired, n (%) ^d	74 (90)	55 (81)
Ethnicity, white British, n (%) ^e	74 (93)	63 (97)
Spirituality, religious, n (%) ^e	52 (68)	44 (70)
Quality of life, poor or very poor, n (%) ^f	29 (35)	37 (53) ^g
Dissatisfied with their health, n (%) ^g	55 (66)	57 (79)
WHO-QOL BREF, mean \pm SD		
QoL physical ^h	36.83 \pm 17.60	30.88 \pm 14.28 ^g
QoL psychological ^h	47.90 \pm 18.42	44.66 \pm 17.04
QoL environment ⁱ	61.15 \pm 16.05	54.36 \pm 13.52 ^g
De Jong Gierveld Loneliness, mean \pm SD		
Social loneliness ^j	1.34 \pm 1.22	1.80 \pm 1.20 ^g
Emotional loneliness ^k	1.80 \pm 1.03	2.03 \pm 1.00
mMOS-SS, mean \pm SD		
MOS instrumental ^l	3.22 \pm 1.26	3.08 \pm 1.38
MOS emotional ^m	3.29 \pm 0.95	2.84 \pm 1.09 ^g
MOS total ⁿ	3.25 \pm 1.01	2.97 \pm 1.09
Network, mean \pm SD ^o	4.52 \pm 2.68	4.54 \pm 2.15
N contacts, mean \pm SD ^p	48.79 \pm 42.75	42.48 \pm 34.65

mMOS-SS = modified Medical Outcomes Study Social Support Survey.

^a $n = 143$, ^b $n = 154$, ^c $n = 152$, ^d $n = 145$, ^e $n = 140$, ^f $N = 82$ & $N = 70$, ^g $N = 83$ & $N = 72$, ^h $N = 82$ & $N = 71$, ⁱ $N = 83$ & $N = 71$, ^j $N = 76$ & $N = 69$, ^k $N = 76$ & $N = 67$, ^l $N = 76$ & $N = 65$, ^m $N = 79$ & $N = 66$, ⁿ $N = 78$ & $N = 65$, ^o $N = 81$ & $N = 68$, ^p $N = 80$ & $N = 66$.

The WHOQOL BREF comprises four individually scored domains. Domain scores are calculated by computing the mean scores within the domain, noting that negatively phrased questions are reverse scored. Domain scores are transformed to a 0–100 scale according to the formula in the WHOQOL Manual. Lower scores indicate a worse quality of life.

^g $P < 0.05$.

There were significant differences between baseline scores on areas of quality of life (d 's = 0.37 to 0.45), social loneliness ($d = 0.37$), and emotional social support ($d = 0.44$) between those with and without cancer. Those with nonmalignant life-limiting disease typically had worse quality of life, were lonelier, and had less social support on referral to the volunteer-provided palliative care services. All differences reflect small effect sizes.

We evaluated the distribution of quality of life at different time points by group. Despite the impact of attrition on our sample, we observed a normal distribution, with good coverage of spread of scores (Table 2, Fig. 2).

By the end of the study, 31 people in this sample had died, 27 of those with cancer and four of those with nonmalignant disease. Data on change in quality of life are reported in Table 3 for the physical, psychological, and environmental domains of the WHO-QOL-BREF.

While people with cancer have a generally higher quality of life at referral to the volunteer-provided palliative care service (baseline), their quality of life deteriorates significantly more rapidly over the (relatively short) data collection period to the end of the study compared to those without cancer (Figs. 3 and 4).

Discussion

These are novel longitudinal quality of life data from those anticipated to be in their last year of life who were referred to volunteer-provided palliative care services. At referral to the service (baseline), demographic characteristics of those with and without cancer are similar, but those with nonmalignant life-limiting illnesses had a worse quality of life, were lonelier, and had less social support. This may indicate they had more need for palliative care services at the time of referral. During the relatively short (12-week) period of data collection, however, those with a cancer diagnosis had a more rapidly deteriorating quality of life. More people with cancer died during the study period. These are different trajectories of quality of life for people with cancer and noncancer diagnoses who were nevertheless identified as requiring similar volunteer-provided palliative care services.

The baseline quality of life scores of those referred to the volunteer-provided palliative care services can be compared to reference data. This demonstrates that quality of life of both those with and without cancer in this sample is worse than people who are healthy or in the general population,^{60–62} but with similarities to those known to have life-limiting illness or be users of specialist palliative care.^{63–65} This may indicate that the triggers for referral, at least in terms

Table 2
Distribution of Quality of Life Scores at Different Time Points

Time	Diagnosis	Variable	N	Mean	Median	Skewness	Kurtosis	SD	Variance
0	Noncancer	QOL physical	72	30.8879	29.16667	0.4409	0.090347	14.27733	203.8421
		QOL environmental	71	54.35775	53.125	-0.03246	0.203167	13.52299	182.8711
		QOL psychological	71	44.65962	45.83333	-0.22528	-0.31619	17.03555	290.2099
	Cancer	QOL physical	83	36.83161	39.28571	-0.01353	-0.58801	17.60223	309.8387
		QOL environmental	83	61.14637	60.71429	-0.24406	-0.11443	16.05305	257.7003
		QOL psychological	82	47.89634	45.83333	-0.18262	-0.53614	18.42487	339.4757
1	Noncancer	QOL physical	47	30.50152	25	0.291113	-0.43105	14.8565	220.7156
		QOL environmental	47	53.48594	56.25	-0.2429	-0.0934	14.91674	222.5093
		QOL psychological	48	42.38715	41.66667	-0.22073	0.238343	17.49467	306.0634
	Cancer	QOL physical	48	35.40427	32.14286	0.090782	-0.86012	17.14556	293.9703
		QOL environmental	48	55.01612	56.25	-0.64922	0.580644	14.72829	216.9224
		QOL psychological	46	47.86232	50	-0.38921	0.501916	16.95642	287.5201
2	Noncancer	QOL physical	46	32.70445	32.14286	0.088838	-0.05852	15.88913	252.4645
		QOL environmental	45	57.41071	56.25	-0.1325	0.358872	12.52476	156.8696
		QOL psychological	46	43.9221	45.83333	-0.18739	-0.40717	18.01375	324.4952
	Cancer	QOL physical	30	37.95635	37.5	0.220681	-0.64456	20.71287	429.0231
		QOL environmental	30	58.79464	61.60714	-0.34316	-0.32883	14.89851	221.9656
		QOL psychological	30	48.66667	50	-0.575	0.115377	18.51607	342.8448
3	Noncancer	QOL physical	17	27.94118	28.57143	-0.04435	-0.1342	15.24041	232.27
		QOL environmental	17	53.41387	53.125	0.229603	-0.76565	11.06538	122.4425
		QOL psychological	17	36.71569	40	-0.19827	0.134167	16.28327	265.145
	Cancer	QOL physical	9	36.50794	35.71429	0.267389	-1.65304	17.29267	299.0363
		QOL environmental	9	50.69444	56.25	-1.08959	0.532079	19.87373	394.9653
		QOL psychological	9	39.35185	41.66667	0.023963	1.566445	17.06695	291.2809

QOL = quality of life.

of need relating to quality of life, are similar both where referral to volunteer-provided palliative care services and a specialist palliative care service are considered. Minimal clinically important differences are not reported for the WHOQOL-BREF, but it has been reported to be sensitive to change in health status.⁶² Typically half an SD is considered a clinically relevant change in health-related quality of life,^{66,67} a magnitude similar to the estimated change observed in our sample at the end of the study.

People with life-limiting illness who do not have cancer are known to be referred to services at a point in time where their functional status is typically worse than those with cancer. For example, those referred to specialist palliative care services with primary diagnoses other than cancer have been found to be less functional at time of referral (odds ratio: 1.6; 95% CI: 1.1–2.3). This was felt to be because of the slower and more varied trajectory of noncancer serious illness, typified by greater disability.^{40,68} Our data




Fig. 2. Distribution of quality of life scores at different time points.

Table 3
Change in Quality of Life Over Time

Variables	<i>b</i>	<i>se</i>	95% CI
WHOQOL BREF physical domain			
Intercept	30.51	1.86	26.86, 34.16
Time	0.41	0.67	-0.91, 1.73
Cancer condition, yes	6.49	2.54	1.51, 11.47
Cancer condition × time	-2.35	1.09	-4.49, -0.21
WHOQOL BREF psychological domain			
Intercept	43.99	2.05	39.98, 48.01
Time	-0.18	0.84	-1.83, 1.47
Cancer condition, yes	4.78	2.80	-0.71, 10.27
Cancer condition × time	-1.32	1.36	-3.98, 1.34
WHOQOL BREF environmental domain			
Intercept	54.05	1.73	50.66, 57.45
Time	0.81	0.76	-0.68, 2.30
Cancer condition, yes	6.54	2.36	1.91, 11.17
Cancer condition × time	-4.11	1.20	-6.45, -1.76

Values in bold are statistically significant.

are important as they identify that this differentiation in baseline status (whether in quality of life or functional status) at point of referral to services is also true for referral to a very different volunteer-provided palliative care services as for referral to specialist palliative care. Specialist palliative care is typically triggered later in the disease course for those without cancer,^{3,69} but this may not necessarily have been expected for those referred to a volunteer-provided palliative care service. People with non-cancer life-limiting disease appear to have been deteriorating for a longer period, with more impact on quality of life, before need is recognized and referral to services made. Reasons for this may include having more time to adapt to a lower functional status, less appreciation of the life-limiting nature of the illness,

less routine assessment of need, or discrimination against some disease, for example, COPD where lifestyle behaviors such as smoking contribute to risk.⁷⁰⁻⁷² In the U.K., hospice and palliative care services are also historically focused on, and predominantly used by, those with cancer.^{3,73}

Even over the relatively short period, data were collected for this study; people with cancer demonstrated a more rapid deterioration in quality of life. Comparisons with other studies are challenging, as many only include people with a single diagnosis, typically cancer, but not with a comparison to other disease trajectories.^{28,30-32,37,42,44,74-77} These studies show that people with cancer do report poorer quality of life over time,⁴⁴ which is broadly characterized as a gradual decline, accelerating in the last months of life. There are studies however which do not demonstrate such changes, with no changes in quality of life found in those referred to a community palliative care service,⁴⁶ and a study of those with lung cancer which found that those with good quality of life did not change as they approached the end of life.⁴⁵ Where studies do compare people with and without cancer, typically steeper declines are found in functional status or quality of life for those with cancer,^{33,34,39} with more disability three months before death.¹² Our study adds to this scarce comparative literature, strengthening the evidence base on the different trajectories of those with and without cancer at the end of life. In particular, our study adds data on quality of life rather than the more typical functional status, prospectively gathered, rather than judged retrospectively from death.




Fig. 3. Change in quality of life (physical domain) over study data collection time points.




Fig. 4. Change in quality of life (environmental domain) over study data collection time points.

The strengths of this study are in the relatively large sample, with different life-limiting illnesses, providing data prospectively over a number of time points. The follow-up time points were carefully and deliberately chosen to be short, given that the study was at the end of life, and care effects need to be rapid to be worthwhile, but it is possible that a longer term follow-up may reveal different trends. A potential limitation is that these data were provided in the context of an interventional trial, and this may affect people's responses to outcome measures in unanticipated ways. Diagnosis data were unavailable for 20 participants, and they had to be removed from this data set; we did not have direct access to clinical data to address this issue. This lack of access to clinical data meant that we do not know if participants were receiving any potentially disease-modifying treatments that could affect quality of life. It is known that the predictive value of the surprise question in identifying those who may die is not perfect, with worse performance in noncancer illness.⁷⁸ It may be that some of those referred are not in their last year of life, with differences in prediction between those with and without cancer. This may be why fewer of those who died were in the noncancer group. However, the baseline data from both groups, and comparison to population norms, nevertheless indicate that these are groups eligible for palliative care, and we carefully controlled for survival differences in our joint model. Our data reflect "real-life" referral patterns to a novel intervention, rather than the sample being representative of these diagnostic populations, and there is strength in these data because of this diversity. We aggregated quality of life data for those with nonmalignant

conditions, as it is known that those with chronic conditions do have similar quality of life trends,⁶² but it must be noted that their patterns of quality of life may not be the same. Our study adds to knowledge methodologically by using joint models that take into account the effect of participants who die earlier in the study. Information on the deaths of those in the study was provided contemporaneously, but exact dates of death were not known for some, and it is possible that some of those for whom we had missing data may have died.

People with life-limiting illness appear to be referred to volunteer-provided palliative care services both close to death (for those with cancer) and with a poor quality of life (for those with nonmalignant disease). The rapid decline in quality of life experienced by those with cancer may indicate that their support needs are greater in this phase of life, potentially necessitating additional support from volunteers in addition to clinical services.

Disclosures and Acknowledgments

The authors acknowledge the contribution of the people who took part in this research, often at a time of great challenge in their lives, thank you. This study would not have been possible without the support of the participating sites, who were responsible for identifying participants, taking consent, and managing study participants and site-specific documentation as well as training volunteers and managing the befriending services. With thanks to Dr. Evangelia (Evie) Papavasiliou, Research Associate on the project to 15.9.15 who was involved in trial initiation

procedures and initial data collection, and Paul Sharples, Research Intern on the project 11.1.16–15.4.16 who assisted with data entry and initial data analysis.

This research was funded by the UK Cabinet Office, who also provided grants to sites to cover the cost of the intervention. The views expressed are those of the authors, not necessarily those of the Cabinet Office. The funders had no role in collection, analysis, or interpretation of data or in the writing of the report. Reports are seen by them before submission, but they have no contribution to the writing or amendment of the report.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The trial was prospectively registered. ISRCTN 12929812 <http://www.isrctn.com/ISRCTN12929812> Health Research Authority research ethics approval was granted 12.3.15 by NRES Committee Yorkshire & The Humber—South Yorkshire. REC reference 15/YH/0090. IRAS project ID 173058. Site specific approvals were granted by NRES Committee Yorkshire and the Humber—South Yorkshire. Informed consent was obtained from all individual participants included in the study.

Availability of data and materials: Patient-level data are stored in the ELSA database developed by the study authors on a secure server maintained by Lancaster University. Presented data are fully anonymized. The corresponding author may be contacted to forward requests for data sharing.

The authors declare they have no competing interests.

References

- Gawande A. Quantity and quality of life: duties of care in life-limiting illness. *JAMA* 2016;315:267–269.
- Wang SY, Hall J, Pollack CE, et al. Trends in end-of-life cancer care in the Medicare program. *J Geriatr Oncol* 2016;7:116–125.
- Allsop MJ, Ziegler LE, Mulvey MR, Russell S, Taylor R, Bennett MI. Duration and determinants of hospice-based specialist palliative care: a national retrospective cohort study. *Palliat Med* 2018;32:1322–1333.
- Lorhan S, Dennis D, van der Westhuizen M, Hodgson S, Berrang T, Daudt H. The experience of people with lung cancer with a volunteer-based lay navigation intervention at an outpatient cancer center. *Patient Educ Couns* 2014;96:237–248.
- Candy B, France R, Low J, Sampson L. Does involving volunteers in the provision of palliative care make a difference to patient and family wellbeing? A systematic review of quantitative and qualitative evidence. *Int J Nurs Stud* 2015;52:756–768.
- Walshe C, Dodd S, Hill M, et al. How effective are volunteers at supporting people in their last year of life? A pragmatic randomised wait-list trial in palliative care (ELSA). *BMC Med* 2016;14:203.
- Gaertner J, Siemens W, Meerpohl JJ, et al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. *BMJ* 2017;357:j2925.
- Kavalieratos D, Corbelli J, Zhang D, et al. Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. *JAMA* 2016;316:2104–2114.
- Haun MW, Estel S, Rucker G, et al. Early palliative care for adults with advanced cancer. *Cochrane database Syst Rev* 2017:CD011129.
- Mather H, Guo P, Firth A, et al. Phase of Illness in palliative care: cross-sectional analysis of clinical data from community, hospital and hospice patients. *Palliat Med* 2017;32:404–412.
- Masso M, Allingham SF, Banfield M, et al. Palliative Care Phase: inter-rater reliability and acceptability in a national study. *Palliat Med* 2015;29:22–30.
- Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. *JAMA* 2003;289:2387–2392.
- Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MAG, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. *Qual Life Res* 2006;15:1533–1550.
- Preston NJ, Fayers P, Walters SJ, et al. Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research: Part of the MORE-Care research method guidance on statistical issues. *Palliat Med* 2013;27:899–907.
- Lynn J, Adamson DM. *Living well at the end of life. Adapting healthcare to serious chronic illness in old age.* Santa Monica, 2003.
- Murray SA, Kendall M, Grant E, Boyd K, Barclay S, Sheikh A. Patterns of social, psychological, and spiritual decline toward the end of life in lung cancer and heart failure. *J Pain Symptom Manage* 2007;34:393–402.
- Boyd K, Murray SA, Kendall M, Worth A, Benton TF, Clausen H. Living with advanced heart failure: a prospective, community based study of patients and their carers. *The Eur J Heart Fail* 2004;6:585–591.
- Carduff E, Kendall M, Murray SA. Living and dying with metastatic bowel cancer: serial in-depth interviews with patients. *Eur J Cancer Care (Engl)* 2017;27.
- Kendall M, Carduff E, Lloyd A, et al. Different experiences and goals in different advanced diseases: comparing serial interviews with patients with cancer, organ failure, or frailty and their family and professional carers. *J Pain Symptom Manage* 2015;50:216–224.
- Kimbell B, Boyd K, Kendall M, Iredale J, Murray SA. Managing uncertainty in advanced liver disease: a qualitative, multiperspective, serial interview study. *BMJ open* 2015;5:e009241.
- Lloyd A, Kendall M, Starr JM, Murray SA. Physical, social, psychological and existential trajectories of loss and

- adaptation towards the end of life for older people living with frailty: a serial interview study. *BMC Geriatr* 2016;16:176.
22. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. *Br Med J* 2002;325:933.
23. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. *BMJ: Br Med J* 2005;330:1007.
24. Pinnock H, Kendall M, Murray SA, et al. Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. *BMJ Support Palliat Care* 2011;1:174–183.
25. Beernaert K, Deliëns L, De Vleminck A, et al. Is there a need for early palliative care in patients with life-limiting illnesses? Interview study with patients about experienced care needs from diagnosis onward. *Am J Hosp Palliat Care* 2016;33:489–497.
26. Ek K, Andershed B, Sahlberg-Blom E, Ternstedt BM. “The unpredictable death”-The last year of life for patients with advanced COPD: relatives’ stories. *Palliat Support Care* 2015;13:1213–1222.
27. Cawley D, Billings J, Oliver D, Kendall M, Pinnock H. Potential triggers for the holistic assessment of people with severe chronic obstructive pulmonary disease: analysis of multiperspective, serial qualitative interviews. *BMJ Support Palliat Care* 2014;4:152–160.
28. Reed E, Corner J. Defining the illness trajectory of metastatic breast cancer. *BMJ Support Palliat Care* 2015;5:358–365.
29. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *The Lancet* 2012;380:37–43.
30. Hwang SS, Chang VT, Fairclough DL, Cogswell J, Kasimis B. Longitudinal quality of life in advanced cancer patients: pilot study results from a VA medical cancer center. *J Pain Symptom Manage* 2003;25:225–235.
31. Abernethy AP, Kutner J, Levy C, et al. Trajectories of performance status decline in advanced cancer. *J Clin Oncol* 2014;32(suppl):100.
32. Rowland MR, Moore KN, Lefkowitz C, et al. How do palliative care needs vary across the disease trajectory in patients with gynecologic cancer? *J Clin Oncol* 2015;33(suppl):106.
33. Harris P, Wong E, Farrington S, et al. Patterns of functional decline in hospice: what can individuals and their families expect? *J Am Geriatr Soc* 2013;61:413–417.
34. Downey L, Engelberg RA. Quality-of-life trajectories at the end of life: assessments over time by patients with and without cancer. *J Am Geriatr Soc* 2010;58:472–479.
35. Lee MK, Baek SK, Kim S-y, et al. Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: a prospective cohort study. *Palliat Med* 2013;27:144–154.
36. Kilshaw L, Sammut H, Asher R, Williams P, Saxena R, Howse M. A study to describe the health trajectory of patients with advanced renal disease who choose not to receive dialysis. *Clin Kidney J* 2016;9:470–475.
37. Stukenborg GJ, Blackhall LJ, Harrison JH, Dillon PM, Read PW. Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. *Support Care Cancer* 2016;24:2217–2224.
38. Chen J-H, Chan D-C, Kiely DK, Morris JN, Mitchell SL. Terminal trajectories of functional decline in the long-term care setting. *J Gerontol A Biol Sci Med Sci* 2007;62:531–536.
39. Teno JM, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases. *J Palliat Med* 2001;4:457–464.
40. Stabenau HF, Morrison LJ, Gahbauer EA, Leo-Summers L, Allore HG, Gill TM. Functional trajectories in the year before hospice. *Ann Fam Med* 2015;13:33–40.
41. Flint KM, Schmiede SJ, Allen LA, Fendler TJ, Rumsfeld J, Bekelman D. Health status trajectories among outpatients with heart failure. *J Pain Symptom Manage* 2017;53:224–231.
42. Tang ST, Liu LN, Lin KC, et al. Trajectories of the multidimensional dying experience for terminally ill cancer patients. *J Pain Symptom Manage* 2014;48:863–874.
43. Murtagh FE, Sheerin NS, Addington-Hall J, Higginson IJ. Trajectories of illness in stage 5 chronic kidney disease: a longitudinal study of patient symptoms and concerns in the last year of life. *Clin J Am Soc Nephrol: CJASN* 2011;6:1580–1590.
44. Beernaert K, Pardon K, Van den Block L, et al. Palliative care needs at different phases in the illness trajectory: a survey study in patients with cancer. *Eur J Cancer Care (Engl)* 2016;25:534–543.
45. Hermann CP, Looney SW. Determinants of quality of life in patients near the end of life: a longitudinal perspective. *Oncol Nurs Forum* 2011;38:23–31.
46. Connell T, Griffiths R, Fernandez RS, Tran D, Agar M, Harlum J. Quality-of-life trajectory of clients and carers referred to a community palliative care service. *Int J Palliat Nurs* 2011;17:80–85.
47. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. *J Clin Oncol* 2011;29:1151–1158.
48. Amblas-Novellas J, Murray SA, Espauella J, et al. Identifying patients with advanced chronic conditions for a progressive palliative care approach: a cross-sectional study of prognostic indicators related to end-of-life trajectories. *BMJ open* 2016;6:e012340.
49. Tayjasant S, Bruera E, Hui D. How far along the disease trajectory? An examination of the time-related patient characteristics in the palliative oncology literature. *Support Care Cancer* 2016;24:3997–4004.
50. Walshe C, Perez AG, Dodd SR, et al. Protocol for the End-of-Life Social Action Study (ELSA): a randomised wait-list controlled trial and embedded qualitative case study evaluation assessing the causal impact of social action befriending services on end of life experience. *BMC Palliat Care* 2016;15:60.
51. Dodd S, Hill M, Ockenden N, et al. ‘Being with’ or ‘doing for’? How the role of an end-of-life volunteer befriender can impact patient wellbeing: interviews from a multiple qualitative case study (ELSA). *Support Care Cancer* 2018;26:3163–3172.

52. Moss AH, Lunney JR, Culp S, et al. Prognostic significance of the “surprise” question in cancer patients. *ASCO Meet Abstr* 2009;27:9588.
53. Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL Group. *Qual Life Res* 2004;13:299–310.
54. De Jong Gierveld J, van Tilburg T. The De Jong Gierveld short scales for emotional and social loneliness: tested on data from 7 countries in the UN generations and gender surveys. *Eur J Ageing* 2010;7:121–130.
55. Moser AF, Stuck AE FAU - Silliman R, Silliman RA FAU - Ganz P, Ganz PA FAU - Clough-Gorr K, Clough-Gorr KM. The eight-item modified Medical Outcomes Study Social Support Survey: psychometric evaluation showed excellent performance. (1878-5921 [Electronic]). *J Clin Epidemiol* 2012;65:1107–1116.
56. Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. *Stat Sinica* 2004; 809–834.
57. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. *Biostatistics* 2000;1:465–480.
58. Murphy T, Han L, Allore H, Peduzzi P, Gill T, Lin H. Treatment of death in the analysis of longitudinal studies of gerontological outcomes. *Journals Gerontol Ser A: Biomed Sci Med Sci* 2010;66:109–114.
59. Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. *J Stat Softw* (online) 2010;35:1–33.
60. Hawthorne G, Herrman H, Murphy B. Interpreting the WHOQOL-Bref: preliminary population norms and effect sizes. *Social Indicators Res* 2006;77:37–59.
61. Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen N-A, Bech P. Quality of life in the Danish general population – normative data and validity of WHOQOL-BREF using Rasch and item response theory models. *Qual Life Res* 2004;13:531–540.
62. Skevington SM, McCrate FM. Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. *Health Expect* 2011;15:49–62.
63. Svensk AC, Öster I, Thyme KE, et al. Art therapy improves experienced quality of life among women undergoing treatment for breast cancer: a randomized controlled study. *Eur J Cancer Care* 2009;18:69–77.
64. Lo Coco G, Lo Coco D, Cicero V, et al. Individual and health-related quality of life assessment in amyotrophic lateral sclerosis patients and their caregivers. *J Neurol Sci* 2005;238:11–17.
65. Galfin JM, Watkins ER, Harlow T. A brief guided self-help intervention for psychological distress in palliative care patients: a randomised controlled trial. *Palliat Med* 2012;26:197–205.
66. Den Oudsten BL, Zijlstra WP, De Vries J. The minimal clinically important difference in the World Health Organization Quality of Life instrument—100. *Support Care Cancer* 2013;21:1295–1301.
67. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Med Care* 2003; 582–592.
68. Bostwick D, Wolf S, Samsa G, et al. Comparing the palliative care needs of those with cancer to those with common non-cancer serious illness. *J Pain Symptom Manage* 2017;53: 1079–1084.e1.
69. Kralik D, Anderson B. Differences in home-based palliative care service utilisation of people with cancer and non-cancer conditions. *J Clin Nurs* 2008;17:429–435.
70. Disler RT, Green A, Lockett T, et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. *J Pain Symptom Manage* 2014;48:1182–1199.
71. Elkington H, White P, ddington-Hall J, Higgs R, Pettinari C. The last year of life of COPD: a qualitative study of symptoms and services. *Respir Med* 2004;98:439–445.
72. Winstanley L, Daunt M, Macfarlane J. Doctors’ attitude towards current smokers with chronic obstructive pulmonary disease and its impact on delivering smoking cessation advice. *J Smoking Cessation* 2008;3:133–135.
73. Walshe C, Todd C, Caress A, Chew-Graham C. Patterns of access to community palliative care services: a literature review. *J Pain Symptom Manage* 2009;37:884–912.
74. Lee MK, Lee WJ, Do YR, et al. Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: multicenter prospective cohort study. *Palliat Support Care* 2015;13:1103–1111.
75. Lam WW, Soong I, Yau TK, et al. The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study. *Psychooncology* 2013;22:2831–2839.
76. Lo C, Zimmermann C, Rydall A, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. *J Clin Oncol* 2010;28: 3084–3089.
77. Gott M, Barnes S, Parker C, et al. Dying trajectories in heart failure. *Palliat Med* 2007;21:95–99.
78. Downar J, Goldman R, Pinto R, Englesakis M, Adhikari NKJ. The “surprise question” for predicting death in seriously ill patients: a systematic review and meta-analysis. *CMAJ: Can Med Assoc J* 2017;189:E484–E493.